SCHEMBL6137571

SCHEMBL6137571

C#CC(Cc1ccccc1)O[Si](C)(C)C(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 0.40
CYP1A2 P05177 3/20 0.38
CYP2D6 P10635 2/20 0.38
TSHR P16473 2/20 0.38
CYP3A4 P08684 1/20 0.38
MAOA P21397 5/20 0.36
ADRA2A P08913 1/20 0.36
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36
ADRA1A P35348 1/20 0.36
SNCA P37840 1/20 0.36
OPRK1 P41145 1/20 0.36
PKM P14618 1/20 0.36
MAPK1 P28482 1/20 0.36
KDM4E B2RXH2 1/20 0.36
TAAR1 Q96RJ0 3/20 0.34
SLC6A2 P23975 2/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34
SIGMAR1 Q99720 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6137564 1.00 MAOB (0.40) MAOBCYP1A2CYP2D6TSHRCYP3A4
SCHEMBL9793858 0.85 BLM (0.35) KDM4E
SCHEMBL7547751 0.85 BLM (0.35) KDM4E
SCHEMBL8996048 0.84 ANPEP (0.36) MAOBMAOATAAR1SLC6A2SLC6A4
SCHEMBL6377017 0.82 SLC16A3 (0.33) TAAR1
SCHEMBL7655260 0.82 SLC16A3 (0.33) TAAR1
SCHEMBL9794051 0.81 HTR2A (0.49) MAOBCYP1A2CYP2D6TSHRCYP3A4
SCHEMBL9794039 0.81 HTR2A (0.49) MAOBCYP1A2CYP2D6TSHRCYP3A4
SCHEMBL6137281 0.79 CYP2D6 (0.42) MAOBCYP1A2CYP2D6CYP3A4MAOA
SCHEMBL9794052 0.79 CYP2D6 (0.42) MAOBCYP1A2CYP2D6CYP3A4MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1436252-A4 HYDROXYFATTYSULFONIC ACID ANALOGS TAISHO PHARMACEUTICAL CO LTD (JP) 2005-02-09 EP disclosed
US-20050020680-A1 Hydroxyfattysulfonic acid analogs BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2005-01-27 US disclosed
EP-1436252-A1 HYDROXYFATTYSULFONIC ACID ANALOGS TAISHO PHARMACEUTICAL CO., LTD (JP) 2004-07-14 EP disclosed
WO-2003024922-A1 HYDROXYFATTYSULFONIC ACID ANALOGS TAISHO PHARMACEUTICAL CO., LTD. (JP) 2003-03-27 WO disclosed
EP-0255098-B1 Novel 8-(lower alkyl) bicyclo [4.2.0] octane derivatives with valuable therapeutic properties SYNTEX (U.S.A.) INC. (US) 1991-05-29 EP disclosed
US-4983627-A Treating atherosclerosis, thrombosis and vasospasms; anticholesterol,-secretory,-ulcer and hypotensive agents SYNTEX (U.S.A.) INC. (US) 1991-01-08 US disclosed
EP-0196617-B1 [4.2.0]bicyclooctane derivatives, process for their preparation and pharmaceutical compositions containing same SYNTEX (U.S.A.) INC. (US) 1989-05-31 EP disclosed
US-4822804-A 5,6,7,-trinor-4,8-inter-m-phenylene 2-nor PGI2 derivatives and anti-ulcer, anti-thrombotic and anti-hypertensive pharmaceutical compositions containing them TORAY INDUSTRIES, INC. (JP) 1989-04-18 US disclosed
US-4735966-A ANTICOAGULANTS, VASODILATORS, HYPOTENSIVE AND ANTICHOLESTEROL AGENTS SYNTEX (U.S.A.) INC. (US) 1988-04-05 US disclosed
EP-0257609-A2 Novel substituted (4.2.0)Bicyclooctane derivatives with valuable therapeutic properties SYNTEX (U.S.A.) INC. (US) 1988-03-02 EP disclosed
EP-0255098-A1 Novel 8-(lower alkyl) bicyclo [4.2.0] octane derivatives with valuable therapeutic properties SYNTEX (U.S.A.) INC. (US) 1988-02-03 EP disclosed
US-4678805-A Novel 8-(lower alkyl)bicyclo[4.2.0]octane derivatives with valuable therapeutic properties SYNTEX (U.S.A.) INC. (US) 1987-07-07 US disclosed
EP-0196617-A1 [4.2.0]bicyclooctane derivatives, process for their preparation and pharmaceutical compositions containing same SYNTEX (U.S.A.) INC. (US) 1986-10-08 EP disclosed
US-4608388-A Novel [4,2,0]bicyclooctane derivatives with valuable therapeutic properties SYNTEX (U.S.A.) INC. (US) 1986-08-26 US disclosed
EP-0100900-B1 NOVEL (3.2.0.) BICYCLOHEPTANONE OXIME ETHERS WITH VALUABLE THERAPEUTIC PROPERTIES SYNTEX (U.S.A.) INC. (US) 1986-02-05 EP disclosed
US-4564620-A 5,6,7,-Trinor-4,8-inter-m-phenylene PGI2 derivatives and anti-ulcer, anti-thrombotic and anti-hypertensive pharmaceutical compositions containing them TORAY INDUSTRIES, INC. (JP) 1986-01-14 US disclosed
US-4552898-A CARDIOVASCULAR DISORDERS SYNTEX (U.S.A.) INC. (US) 1985-11-12 US disclosed
EP-0100900-A1 Novel (3.2.0.) bicycloheptanone oxime ethers with valuable therapeutic properties SYNTEX (U.S.A.) INC. (US) 1984-02-22 EP disclosed
US-4423068-A (3.2.0) Bicycloheptanone oxime ethers with therapeutic properties SYNTEX (U.S.A.) INC. (US) 1983-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020680-A1 Hydroxyfattysulfonic acid analogs ELANE, HRH2, APEH MAOB 1450/4885CYP1A2 1534/4885CYP2D6 481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.